These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 19245679)

  • 1. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
    Taylor DM; Smith L
    Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of clozapine with a second antipsychotic - a meta-analysis.
    Taylor DM; Smith L; Gee SH; Nielsen J
    Acta Psychiatr Scand; 2012 Jan; 125(1):15-24. PubMed ID: 22077319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of a randomized switch of patients from clozaril to generic clozapine.
    Kluznik JC; Walbek NH; Farnsworth MG; Melstrom K
    J Clin Psychiatry; 2001; 62 Suppl 5():14-7; discussion 23-4. PubMed ID: 11305843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
    Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
    Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis.
    Paton C; Whittington C; Barnes TR
    J Clin Psychopharmacol; 2007 Apr; 27(2):198-204. PubMed ID: 17414246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine.
    Munro J; Matthiasson P; Osborne S; Travis M; Purcell S; Cobb AM; Launer M; Beer MD; Kerwin R
    Acta Psychiatr Scand; 2004 Oct; 110(4):292-8. PubMed ID: 15352931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
    Henderson DC; Goff DC
    J Clin Psychiatry; 1996 Sep; 57(9):395-7. PubMed ID: 9746446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study.
    Stryjer R; Strous R; Bar F; Shaked G; Shiloh R; Rozencwaig S; Grupper D; Buchman N; Kotler M; Rabey JM; Weizman A
    Hum Psychopharmacol; 2004 Jul; 19(5):343-6. PubMed ID: 15252826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.
    Raskin S; Katz G; Zislin Z; Knobler HY; Durst R
    Acta Psychiatr Scand; 2000 Apr; 101(4):334-6. PubMed ID: 10782556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study.
    Nielsen J; Emborg C; Gydesen S; Dybbro J; Aagaard J; Haderup K; Glyngdal P; Fabricius S; Thode D; Lublin H; Andersen T; Damkier P; Taylor D
    J Clin Psychopharmacol; 2012 Apr; 32(2):173-8. PubMed ID: 22367659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M; Kuwilsky A; Krumm B; Dressing H
    J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
    Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
    J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The brief psychiatric rating scale: effect of scaling system on clinical response assessment.
    Thompson PA; Buckley PF; Meltzer HY
    J Clin Psychopharmacol; 1994 Oct; 14(5):344-6. PubMed ID: 7806691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
    Welge JA; Keck PE
    Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.
    Semiz UB; Cetin M; Basoglu C; Ebrinc S; Uzun O; Herken H; Balibey H; Algul A; Ates A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1330-6. PubMed ID: 17618026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.